Preferential expression and frequent IgG responses of a tumor antigen, SOX5, in glioma patients

Ryo Ueda, Kazunari Yoshida, Takeshi Kawase, Yutaka Kawakami, Masahiro Toda

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

We previously reported to identify SOX5 as a glioma antigen by serological screening using a testis cDNA library. The present study was designed to analyze SOXS expression, its immunoreactivity, and the correlation between SOX5 IgG responses and clinical features in glioma patients to evaluate the possibility of its use as a diagnostic marker. Quantitative RT-PCR and Western blot analysis revealed that SOX5 was expressed in glioma tissues, but not in normal adult tissues, except in the testis. An immunohistochemical analysis showed that SOX5 was expressed in glioma cells, but only a few SOX5-positive cells were detected in non-neoplastic tissues from the cerebral cortex. IgG antibodies against SOX5 were detected in sera from 8 of the 27 glioma patients (27.6%), 0 of the 14 patients with other brain diseases (0%), 1 of the 54 other cancer patients (1.9%) and 1 of the 37 healthy individuals (2.7%). Patients with glioblastotna (GBM) who showed IgG responses against SOX5 exhibited significantly better survival periods than GBM patients without SOX5 antibodies. In summary, SOX5 is aberrantly expressed in glioma and can be recognized as a glioma antigen using IgGs from the sera of glioma patients. Furthermore, there is a statistically significant correlation between the presence of SOX5 IgGs and survival in GBM patients, suggesting that the glioma antigen SOX5 may be useful not only as a diagnostic marker, but also as a prognostic marker in glioma patients.

Original languageEnglish
Pages (from-to)1704-1711
Number of pages8
JournalInternational Journal of Cancer
Volume120
Issue number8
DOIs
Publication statusPublished - 2007 Apr 15

Fingerprint

Neoplasm Antigens
Glioma
Immunoglobulin G
Antigens
Testis
Survival
Antibodies
Brain Diseases
Serum
Gene Library
Cerebral Cortex
Western Blotting
Polymerase Chain Reaction

Keywords

  • Glioma
  • IgG response
  • SEREX
  • SOX5
  • Tumor antigen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Preferential expression and frequent IgG responses of a tumor antigen, SOX5, in glioma patients. / Ueda, Ryo; Yoshida, Kazunari; Kawase, Takeshi; Kawakami, Yutaka; Toda, Masahiro.

In: International Journal of Cancer, Vol. 120, No. 8, 15.04.2007, p. 1704-1711.

Research output: Contribution to journalArticle

@article{b1246c64e2904bc6a3473ad3bf02ab72,
title = "Preferential expression and frequent IgG responses of a tumor antigen, SOX5, in glioma patients",
abstract = "We previously reported to identify SOX5 as a glioma antigen by serological screening using a testis cDNA library. The present study was designed to analyze SOXS expression, its immunoreactivity, and the correlation between SOX5 IgG responses and clinical features in glioma patients to evaluate the possibility of its use as a diagnostic marker. Quantitative RT-PCR and Western blot analysis revealed that SOX5 was expressed in glioma tissues, but not in normal adult tissues, except in the testis. An immunohistochemical analysis showed that SOX5 was expressed in glioma cells, but only a few SOX5-positive cells were detected in non-neoplastic tissues from the cerebral cortex. IgG antibodies against SOX5 were detected in sera from 8 of the 27 glioma patients (27.6{\%}), 0 of the 14 patients with other brain diseases (0{\%}), 1 of the 54 other cancer patients (1.9{\%}) and 1 of the 37 healthy individuals (2.7{\%}). Patients with glioblastotna (GBM) who showed IgG responses against SOX5 exhibited significantly better survival periods than GBM patients without SOX5 antibodies. In summary, SOX5 is aberrantly expressed in glioma and can be recognized as a glioma antigen using IgGs from the sera of glioma patients. Furthermore, there is a statistically significant correlation between the presence of SOX5 IgGs and survival in GBM patients, suggesting that the glioma antigen SOX5 may be useful not only as a diagnostic marker, but also as a prognostic marker in glioma patients.",
keywords = "Glioma, IgG response, SEREX, SOX5, Tumor antigen",
author = "Ryo Ueda and Kazunari Yoshida and Takeshi Kawase and Yutaka Kawakami and Masahiro Toda",
year = "2007",
month = "4",
day = "15",
doi = "10.1002/ijc.22472",
language = "English",
volume = "120",
pages = "1704--1711",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - Preferential expression and frequent IgG responses of a tumor antigen, SOX5, in glioma patients

AU - Ueda, Ryo

AU - Yoshida, Kazunari

AU - Kawase, Takeshi

AU - Kawakami, Yutaka

AU - Toda, Masahiro

PY - 2007/4/15

Y1 - 2007/4/15

N2 - We previously reported to identify SOX5 as a glioma antigen by serological screening using a testis cDNA library. The present study was designed to analyze SOXS expression, its immunoreactivity, and the correlation between SOX5 IgG responses and clinical features in glioma patients to evaluate the possibility of its use as a diagnostic marker. Quantitative RT-PCR and Western blot analysis revealed that SOX5 was expressed in glioma tissues, but not in normal adult tissues, except in the testis. An immunohistochemical analysis showed that SOX5 was expressed in glioma cells, but only a few SOX5-positive cells were detected in non-neoplastic tissues from the cerebral cortex. IgG antibodies against SOX5 were detected in sera from 8 of the 27 glioma patients (27.6%), 0 of the 14 patients with other brain diseases (0%), 1 of the 54 other cancer patients (1.9%) and 1 of the 37 healthy individuals (2.7%). Patients with glioblastotna (GBM) who showed IgG responses against SOX5 exhibited significantly better survival periods than GBM patients without SOX5 antibodies. In summary, SOX5 is aberrantly expressed in glioma and can be recognized as a glioma antigen using IgGs from the sera of glioma patients. Furthermore, there is a statistically significant correlation between the presence of SOX5 IgGs and survival in GBM patients, suggesting that the glioma antigen SOX5 may be useful not only as a diagnostic marker, but also as a prognostic marker in glioma patients.

AB - We previously reported to identify SOX5 as a glioma antigen by serological screening using a testis cDNA library. The present study was designed to analyze SOXS expression, its immunoreactivity, and the correlation between SOX5 IgG responses and clinical features in glioma patients to evaluate the possibility of its use as a diagnostic marker. Quantitative RT-PCR and Western blot analysis revealed that SOX5 was expressed in glioma tissues, but not in normal adult tissues, except in the testis. An immunohistochemical analysis showed that SOX5 was expressed in glioma cells, but only a few SOX5-positive cells were detected in non-neoplastic tissues from the cerebral cortex. IgG antibodies against SOX5 were detected in sera from 8 of the 27 glioma patients (27.6%), 0 of the 14 patients with other brain diseases (0%), 1 of the 54 other cancer patients (1.9%) and 1 of the 37 healthy individuals (2.7%). Patients with glioblastotna (GBM) who showed IgG responses against SOX5 exhibited significantly better survival periods than GBM patients without SOX5 antibodies. In summary, SOX5 is aberrantly expressed in glioma and can be recognized as a glioma antigen using IgGs from the sera of glioma patients. Furthermore, there is a statistically significant correlation between the presence of SOX5 IgGs and survival in GBM patients, suggesting that the glioma antigen SOX5 may be useful not only as a diagnostic marker, but also as a prognostic marker in glioma patients.

KW - Glioma

KW - IgG response

KW - SEREX

KW - SOX5

KW - Tumor antigen

UR - http://www.scopus.com/inward/record.url?scp=33947115905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947115905&partnerID=8YFLogxK

U2 - 10.1002/ijc.22472

DO - 10.1002/ijc.22472

M3 - Article

VL - 120

SP - 1704

EP - 1711

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 8

ER -